MiniMed Group Inc

MMED

Market cap $3.63B

Investment bank Goldman Sachs just came out with calls on two under-the-radar stocks investors should get to know, and the sooner, the better.

NORTHRIDGE, Calif., April 13, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2026 on Wednesday, June 3, 2026.

MiniMed Group (NASDAQ:MMED) has been initiated with a ‘Buy' rating by Bank of America, reflecting the view that the company is approaching a key inflection point following its recent separation from Medtronic. The analysts gave the company, which specializes in developing and manufacturing technology for diabetes management, a $27 price target, implying upside from current levels of about $14.

MiniMed Flex™ is about half the size of the previous generation MiniMed™ 780G system, and features the SmartGuard™ adaptive algorithm to automatically adjust and autocorrect insulin delivery in real-time NORTHRIDGE, Calif., March 18, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced U.S. Food and Drug Administration (FDA) clearance of MiniMed Flex™, a next-generation discreet, smartphone-controlled insulin pump designed to fit seamlessly into everyday life.

NORTHRIDGE, Calif., March 9, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed; Nasdaq: MMED) today announced the closing of its previously announced initial public offering (IPO) of 28,000,000 shares of its common stock at a price to the public of $20.00 per share.